Moreover, both commercial mesothelioma cell lines and primary patient-derived cells (PDCLs) with inherent NF2 deficiency exhibited greater sensitivity to DHODH inhibition compared to NF2-intact counterparts (Figs. 3H,I and  EV4J–M). This evidence concerns the gene NF2 and mesothelioma.